Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Cryoport
CYRX
Cryoport
Rising Biopharma Regulations Will Crimp Expansion But Foster Recovery
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 9 Analysts
Published
10 Aug 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$8.00
7.6% overvalued
intrinsic discount
16 Aug
US$8.61
Loading
1Y
-4.4%
7D
13.9%
Author's Valuation
US$8.0
7.6% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$8.0
7.6% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-297m
241m
2014
2017
2020
2023
2025
2026
2028
Revenue US$193.3m
Earnings US$24.7m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
-1.65%
Life Sciences revenue growth rate
0.33%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
8.19%
Calculation
US$24.75m
Earnings '28
x
21.27x
PE Ratio '28
=
US$526.35m
Market Cap '28
US$526.35m
Market Cap '28
/
52.08m
No. shares '28
=
US$10.11
Share Price '28
US$10.11
Share Price '28
Discounted to 2025 @ 8.16% p.a.
=
US$7.99
Fair Value '25
